KELLY CORREDOR

Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

AMERICAN SOCIETY OF ADDICTION MEDICINE

AMERICAN SOCIETY OF ADDICTION MEDICINE

AMERICAN SOCIETY OF ADDICTION MEDICINE

AMERICAN SOCIETY OF ADDICTION MEDICINE

AMERICAN SOCIETY OF ADDICTION MEDICINE